New asthma inhaler passes first safety check in small study

NCT ID NCT06385964

Completed Symptom relief Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested an experimental drug called SHR-4597, given as an inhaled powder, in 62 healthy volunteers and people with asthma. The main goal was to see if it is safe and tolerable. The study gave single doses to healthy people and multiple doses over several days to asthma patients with mild to severe symptoms. This is a first step to see if the drug is safe enough for further testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-4597 (an experimental drug taken by inhaling a dry powder)
What this could lead to: If safe, this could lead to a new inhaled treatment option for asthma that helps control symptoms.
What could go wrong: This is a very early Phase 1 trial focused only on safety, not on whether the drug works. It is small (62 people) and may not lead to an effective treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMATIC PATIENTS HEALTHY SUBJECTS

Contacts and locations

Locations

West China Hospital of Sichuan University

Chengdu, Sichuan, 200433, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.